Nasus Pharma NSRX
NYSE NSRX
$3.49 +0.43 (+14.05%)
As of: Oct 22, 2026 · 3:58 PM EDT

Nasus Pharma (NSRX) Ending Cash Balance (2024 - 2026)

Updated

Analysis

Nasus Pharma (NSRX) Ending Cash Balance (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Ending Cash Balance (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 8.95 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 16.91 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 6.57 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn 6.89 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 7.62 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 4.88 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 13.99 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn 3.18 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn 1.03 Bn
10 Nasus Pharma 27.16 Mn 10.45 Mn - 7.90 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 7.90 Mn
Dec 31, 2025 1.29 Mn
Jun 30, 2025 232,000.00
Dec 31, 2024 311,000.00
API Access

Nasus Pharma Ending Cash Balance API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ending-cash-balance&ticker=NSRX&period=max&api_key=YOUR_API_KEY